Oral Administration of Peptides; Absorption From Gastrointestinal Tract
Summary
Context: Oral formulations of GLP-1 and PYY3-36, two satiety peptides, were studied. An oral delivery system would be preferable in many of the possible therapeutic indications of these peptides. Objectives: Our objective was to establish the pharmacological profile of increasing oral doses of GLP-1 and PYY3-36 in healthy volunteers. In addition, the pharmacological effects of GLP-1 were investigated. Setting: Single center escalating dose study with oral applications. Subjects and Methods: In the first part, GLP-1 was given orally to 6 male subjects; the treatment consisted of one of the following oral doses of either GLP-1 (0.5, 1.0, 2.0 and 4.0 mg) or placebo. In the second part, PYY3-36 was given orally to another 6 healthy male subjects; the treatment consisted of one of the following oral doses of either PYY3-36 (0.25, 0.5, 1.0, 2.0 and 4.0 mg) or placebo.
Timeline
- Start
- 2006-10
- Primary completion
- —
- Completion
- 2007-02
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLP-1 | Peptide | 0.5 mg | Oral |
| Subject | GLP-1 | Peptide | 1 mg | Oral |
| Subject | GLP-1 | Peptide | 2 mg | Oral |
| Subject | GLP-1 | Peptide | 4 mg | Oral |
| Subject | PEPTIDE YY HUMAN (3-36) | Peptide | 0.25 mg | Oral |
| Subject | PEPTIDE YY HUMAN (3-36) | Peptide | 0.5 mg | Oral |
| Subject | PEPTIDE YY HUMAN (3-36) | Peptide | 1 mg | Oral |
| Subject | PEPTIDE YY HUMAN (3-36) | Peptide | 2 mg | Oral |
| Subject | PEPTIDE YY HUMAN (3-36) | Peptide | 4 mg | Oral |
Indications
No indication recorded.